Does V600E BRAF mutation predict vinorelbine efficacy? A proof-of-concept from a lung micropapillary adenocarcinoma metastatic to the breast

P. Carassai, G. Jocollé, G. Donati, S. Spinazzé, C. Baiocco, P. Baderna, A. Martinet, F. Lococo, F. Migliaccio, G. Rossi

Research output: Contribution to journalArticlepeer-review

Abstract

BRAF mutations occur in about 3% of all lung adenocarcinomas and V600E missense mutation characterizes about half of BRAFmutated lung adenocarcinomas and is significantly associated with micropapillary pattern and shorter disease-free and overall survival rates. In this report, we report a challenging case of a patient with a metastatic micropapillary adenocarcinoma of the lung harbouring V600E BRAF mutation who experienced a surprising protracted clinical response to metronomic vinorelbine. The possible association between the V600E BRAF mutation pathway and the effective use of vinca alkaloid is discussed.

Original languageEnglish
Pages (from-to)426-428
Number of pages3
JournalPathologica
Volume109
Issue number4
Publication statusPublished - Dec 1 2017

Keywords

  • Adenocarcinoma
  • BRAF
  • Breast
  • Lung
  • Metastasis
  • Micropapillary
  • V600E
  • Vinorelbine

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Fingerprint Dive into the research topics of 'Does V600E BRAF mutation predict vinorelbine efficacy? A proof-of-concept from a lung micropapillary adenocarcinoma metastatic to the breast'. Together they form a unique fingerprint.

Cite this